A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: a United States, multicenter trial by Chey, William D. et al.
A Comparison of Three Fingerstick,
Whole Blood Antibody Tests forHelicobacter
pylori Infection: A United States, Multicenter Trial
W. D. Chey, M.D., F.A.C.G., U. Murthy, M.D., S. Shaw, M.D., A. Zawadski, J. Montague,
W. Linscheer, M.D., and L. Laine, M.D.
Divisions of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan; Veteran’s
Administration Medical Center, Syracuse, New York; University of Southern California Medical School, Los
Angeles, California
OBJECTIVE: We compared three whole blood antibody tests
for Helicobacter pylori(H. pylori) in a United States, mul-
ticenter trial.
METHODS: Patients referred for EGD at three medical cen-
ters were recruited. During EGD, biopsies were taken for
histology and rapid urease testing (RUT). Immediately after
endoscopy, patients underwent the antibody tests (FlexPack
HP, Abbott Diagnostics; QuikVue, Quidel Corporation; Ac-
cuMeter, ChemTrak) using whole blood obtained by two to
three fingersticks. Performance characteristics were calcu-
lated for each antibody test using the biopsy-based methods
as a gold standard.
RESULTS: A total of 131 patients participated; 50 (38%)
patients had histological evidence ofH. pylori infection.
Using histology as a gold standard, the sensitivities of Flex-
Pack HP, QuikVue, and Accumeter were 76%, 78%, and
84%, respectively. Specificity was 79% with FlexPack HP
and 90% with QuikVue and Accumeter. There were no
significant differences in the performance of the three anti-
body tests though there was a trend toward superior perfor-
mance for AccuMeter compared to FlexPack HP (p 5
0.019). However, RUT proved superior to FlexPack HP
using histology as a gold standard (p 5 0.008). Using either
concordant histology and RUT results or a positive histol-
ogy or RUT to define activeH. pylori infection, there was no
statistically significant difference between the antibody
tests.
CONCLUSIONS: There were no statistically significant dif-
ferences in the performance of the three antibody tests.
These tests proved only marginally sensitive in detecting
patients infected withH. pylori. Clinicians should be aware
of the limitations of these tests, particularly when using
them as a sole means of testing forH. pylori. (Am J
Gastroenterol 1999;94:1512–1516. © 1999 by Am. Coll. of
Gastroenterology)
INTRODUCTION
Currently available diagnostic tests forHelicobacter pylori
(H. pylori) infection include those requiring upper endos-
copy with biopsy (for histology or rapid urease testing), and
nonendoscopic techniques such as urea breath testing and
serology. Currently, there is no true gold standard for the
diagnosis ofH. pylori infection. Most studies report sensi-
tivities and specificities for histology, rapid urease testing
(RUT), and urea breath testing of.90% (1, 2). Performance
characteristics have been more variable for the serological
tests (3). Serology is currently considered by many to be the
most cost-effective initial diagnostic test for HP infection
(4).
Both quantitative and qualitative antibody tests are com-
mercially available. Quantitative serologic assays (ELISA)
accurately identify infected patients who have not been
previously treated forH. pylori (5). Disadvantages of quan-
titative serology testing include expense, need for specially
trained personnel, and delay between the time the test is
done and when results become available. More recently, a
number of relatively inexpensive, simple to perform, office-
based, qualitative antibody tests forH. pylori have become
available. These qualitative tests can detect specific IgG
antibodies toH. pylori using serum or whole blood. Serum-
based qualitative tests have compared favorably in perfor-
mance to the quantitative serological tests (6, 7), but require
phlebotomy and centrifugation of blood samples. The re-
cently introduced whole blood antibody tests, which use
blood obtained by a fingerstick, offer all of the advantages
of serum-based testing without the need for centrifugation
of blood samples. The low cost, ease of performance, and
rapid results of the whole blood tests make them ideal for
the office-based practitioner, particularly in light of recent
recommendations endorsing a “test and treat” strategy for
young dyspeptic patients without alarm symptoms (8).
However, the reported performance characteristics of the
available whole blood antibody tests has varied consider-
ably in the medical literature (9–15).
The aim of our study was to determine and compare the
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performance characteristics of three whole blood antibody
tests forH. pylori using biopsy-based diagnostic methods as
a gold standard in a United States, multicenter trial.
MATERIALS AND METHODS
Patient Population
Patients referred for upper endoscopy at three geographi-
cally diverse US medical centers were asked to participate in
the study. Patients had to be.18 yr of age and able to
understand and to give written informed consent. Patients
were excluded if they had received treatment forH. pylori
within 1 yr of EGD, antibiotics or bismuth-containing com-
pounds within 1 month of EGD, or a proton pump inhibitor
within 7 days of EGD. This protocol was approved by the
Institutional Review Boards of the participating centers.
Study Protocol
During endoscopy, biopsies were taken from the body (.2)
and antrum (.2) of the stomach for histology (hematoxylin
and eosin in all patients, and Giemsa in patients with his-
tological gastritis but noH. pylori organisms by hematox-
ylin and eosin staining) and rapid urease testing (RUT;
Pyloritek, Serim Research, Elkhart, IN, or Clotest, Trimed
Specialties, Charlottesville, VA). Histology was performed
by experienced gastrointestinal pathologists at each of the
study sites.
Immediately after EGD, patients underwent three whole
blood antibody tests: 1) FlexPack HP (Abbott Diagnostics,
Abbott Park, IL); 2) Quick Vue (Quidel Corporation, San
Diego, CA); and 3) AccuMeter (formerly known as the
HpChek; ChemTrak, Sunnyvale, CA). In all three cases,
antibody testing was performed using whole blood obtained
with two to three fingersticks according to instructions pro-
vided by the manufacturer. The three antibody tests were
performed in a nonrandomized fashion and interpreted by
experienced operators who had no knowledge of the pa-
tient’s endoscopic, RUT, or histological results.
Interpretation of Data and Statistical Analysis
Performance characteristics, including sensitivity, specific-
ity, positive predictive value (PPV), negative predictive
value (NPV), and accuracy were calculated for each whole
blood antibody test using the biopsy-based diagnostic meth-
ods as the gold standard.
We first determined the performance characteristics of the
antibody tests and RUT, using histology alone as a gold
standard.
In our second analysis, activeH. pylori infection was
defined as a positive RUT and histology result. In this
analysis, the presence of negative RUT and histology de-
fined noninfected patients. Patients with discordant RUT
and histology were excluded from this analysis. This type of
analysis should present the “best case scenario” for the
sensitivity and negative predictive value of the antibody
tests.
In the final analysis, we defined activeH. pylori infection
as a positive RUT or histology result. We felt that this
analysis was justified given the outstanding (.95%) spec-
ificity of both RUT and histology. In addition, this analysis
most closely mimics how clinicians use RUT and histology
in clinical practice. This analysis should present the “worst
case scenario” for the sensitivity and negative predictive
value of the antibody tests.
Ninety-five percent confidence intervals were calculated
for the performance characteristics of the RUT and antibody
tests (Tables 1–3). We compared the performance of the
different tests using McNemar’s test. The objective of this
statistical analysis was to determine whether one test agreed
with the gold standard more often than another. For this
analysis, results from a pair of tests were summarized in a
2 3 2 table as agreeing or disagreeing with the gold stan-
dard. The two off-diagonal cells were then compared for
statistically significant differences (agree for test A and
disagree for test B,versusagree for test B and disagree for
test A). A p , 0.017 (0.05/3 comparisons) defined a statis-
tically significant difference between tests.
RESULTS
Patient Population
A total of 131 patients (54 women; mean age 546 2 yr,
range 19–87 yr) participated in the study. The study pop-
ulation consisted of 63% Causcasians, 15% African-Amer-
icans, 16% Hispanic-Americans, and 6% Asian-Americans.
Table 1. Performance Characteristics and 95% Confidence Intervals of the Antibody Tests and RUT Using Histology as a Gold
Standard (n5 131 Patients)
Sensitivity Specificity PPV NPV Accuracy
FlexPack 38/50 (76%) 64/81 (79%) 38/55 (69%) 64/76 (84%) 102/131 (78%)
(62–87%) (69–87%) (55–81%) (74–92%) (71–85%)
QuikVue 39/50 (78%) 73/81 (90%) 39/47 (83%) 73/84 (87%) 112/131 (85%)
(64–88%) (81–96%) (69–92%) (78–93%) (79–91%)
AccuMeter 42/50 (84%) 73/81 (90%) 42/50 (84%) 73/81 (90%) 115/131 (88%)
(71–93%) (81–96%) (71–93%) (81–96%) (82–94%)
RUT 44/50 (88%) 75/81 (93%) 44/50 (88%) 75/81 (93%) 119/131 (91%)
(76–95%) (85–97%) (76–95%) (85–97%) (86–96%)
PPV 5 positive predictive value; NPV5 negative predictive value.
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After a retrospective review of our records, no participants
had been previously treated forH. pylori. Eighteen percent
of patients were found to have peptic ulcer disease at the
time of endoscopy. Operators reported that all three anti-
body tests were easy to perform and to interpret.
Test Characteristics
Fifty (38%) patients had histologic evidence ofH. pylori
infection. Relative to histology, sensitivities of the three
fingerstick antibody tests were 76%, 78%, and 84% for
FlexPack HP, QuickVue, and the AccuMeter, respectively
(Table 1). Specificity was 79% with Flex Pak HP and 90%
for both QuickVue and the AccuMeter. Overall accuracy
ranged from 78% with FlexPack HP to 88% with the Ac-
cumeter. Using McNemar’s test, performance of the three
antibody tests were not statistically significantly different
though a trend toward superior performance of Accumeter
compared to Flex Pack HP was noted (p 5 0.019). Perfor-
mance characteristics were also calculated for the RUT.
Results of the RUT agreed with histology significantly more
commonly than Flex Pack HP (p 5 0.008). The performance
of both QuickVue and the Accumeter were not statistically
significantly different from the RUT.
When concordant histology and RUT results were used as
a gold standard (H. pylori) infection defined as a positive
histology and RUT), 44 (37%) patients were found to be
infected. Twelve patients (9%) with discordant results on
histology and RUT were excluded from this analysis. There
were four patients with discordant histology and RUT re-
sults at each study site. Six patients had a positive RUT and
negative histology and the remaining six had a negative
RUT and positive histology. Using this gold standard, sen-
sitivities for the antibody tests were 77% for FlexPack HP,
82% for QuikVue, and 89% for the AccuMeter (Table 2).
Specificity ranged from a low of 80% with FlexPack HP to
91% and 92% with QuikVue and the Accumeter, respec-
tively. A full accounting of the performance characteristics
using this gold standard is provided in Table 2.
When active infection was defined as a positive histology
or RUT result, 56 (43%) patients were found to be infected
with H. pylori. The 12 patients with discordant histology
and RUT results were included in this analysis. As expected,
sensitivities of the antibody tests decreased using this gold
standard (73% for FlexPack HP, 71% for QuikVue, and
78% for the AccuMeter). Specificities were 81% for Flex-
Pack HP, 91% for QuikVue, and 92% with the AccuMeter
(Table 3). Based on McNemar’s test, there was a trend
toward greater agreement with the gold standard for the
Accumeter when compared with FlexPack HP (p 5 0.021).
DISCUSSION
A recent technical review from the American Gastroenter-
ological Association recommended that young patients with
uncomplicated dyspepsia undergo testing forH. pylori and
receive treatment if infected (8). Such a strategy would be
most effectively carried out with a rapid, easy to perform,
inexpensive test forH. pylori. Such an office-based test
would allow the clinician to decide upon the need forH.
pylori therapy in a single visit, thus obviating the need for
follow-up phone management or a return visit to discuss test
results and/or to initiate therapy. The rapid, qualitative,
office-based antibody tests forH. pylori seem well suited to
such a “test and treat” strategy. The first generation quali-
tative antibody assays required the use of serum, and thus
the inconvenience of phlebotomy and centrifugation of
blood samples. The newer, CLIA-waived whole blood fin-
gerstick tests, however, are inexpensive and are consider-
ably easier and less time consuming to perform. Although
Table 2. Performance Characteristics and 95% Confidence Intervals of the Antibody Tests Using Concordant Histology and RUT
Results as a Gold Standard (n5 119)
Sensitivity Specificity PPV NPV Accuracy
FlexPack 34/44 (77%) 60/75 (80%) 34/49 (69%) 60/70 (86%) 100/119 (84%)
(62–89%) (69–88%) (55–82%) (75–93%) (78–90%)
QuikVue 36/44 (82%) 68/75 (91%) 36/43 (84%) 68/76 (89%) 104/119 (87%)
(67–92%) (82–96%) (69–93%) (81–95%) (81–93%)
AccuMeter 39/44 (89%) 69/75 (92%) 39/45 (87%) 69/74 (93%) 108/119 (91%)
(75–96%) (83–97%) (73–95%) (85–98%) (86–96%)
PPV 5 positive predictive value; NPV5 negative predictive value.
Table 3. Performance Characteristics and 95% Confidence Intervals of the Antibody Tests Using Positive Histology or RUT to Define
Active Infection (n5 131)
Sensitivity Specificity PPV NPV Accuracy
FlexPack 41/56 (73%) 61/75 (81%) 41/55 (75%) 61/76 (80%) 102/131 (78%)
(60–84%) (71–89%) (61–85%) (70–89%) (71–85%)
QuikVue 40/56 (71%) 68/75 (91%) 40/47 (85%) 68/84 (81%) 108/131 (82%)
(58–83%) (82–96%) (72–94%) (71–89%) (75–89%)
AccuMeter 44/56 (79%) 69/75 (92%) 44/50 (88%) 69/81 (85%) 113/131 (86%)
(66–88%) (83–97%) (76–95%) (76–92%) (80–92%)
PPV 5 positive predictive value; NPV5 negative predictive value.
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the whole blood antibody tests offer a potentially attractive
alternative to routine serology or serum-based qualitative
testing, most of the data addressing their performance char-
acteristics has appeared only in abstract form (11–15). The
available studies have reported variable performance char-
acteristics for the whole blood antibody tests with sensitivity
of 70–92% and specificity of 69–95% (9–15).
We report the performance characteristics of three whole
blood antibody tests forH. pylori. Performance character-
istics of FlexPack HP and the AccuMeter in the current
study were comparable to those reported previously (9, 12).
Using histology as a gold standard, there was not a statis-
tically significant difference in the performance character-
istics of the three antibody tests. However, FlexPack HP
agreed significantly less often with a histological gold stan-
dard than the RUT (p 5 0.008). Using a gold standard of
either concordant histology and RUT or a positive histology
or RUT to define activeH. pylori infection, there was no
statistically significant difference among the three antibody
tests. However, using either a positive histology alone (p 5
0.019) or positive histology or RUT (p 5 0.021) to define
active H. pylori infection, there did appear to be a trend
toward superior performance for the AccuMeter when com-
pared with FlexPack HP.
All three of the antibody tests evaluated use the principle
of immunochromatography to detect IgG antibodies toH.
pylori in whole blood, but they differ slightly in their spe-
cific test components. QuickVue and the AccuMeter contain
immobilized purifiedH. pylori antigen in their test lines, but
use different conjugates to detect patient antibodies toH.
pylori. QuickVue uses labeled monoclonal anti-human IgG
antibodies, whereas AccuMeter uses labeled “Protein G”,
which is a protein conjugate that binds IgG antibodies toH.
pylori. The FlexPack HP test contains immobilized anti-
human IgG, while using labeledH. pylori antigen as its
conjugate. It is unclear whether these differences affect their
performance characteristics, or whether other factors such as
the use of differentH. pylori antigens (which may vary
between strains of the organism), differences in the test kit
microenvironments (which may affect ligand binding kinet-
ics), or regional differences in pretest likelihood of infection
are important.
Interestingly, performance characteristics of the three an-
tibody tests did vary among the different study sites. Un-
fortunately, the relatively small numbers of patients at the
individual sites precluded a detailed statistical comparison
of the antibody tests. For this reason, these data have not
been included in this article. The pretest probability ofH.
pylori infection was at least partially responsible for the
regional variation in the positive and negative predictive
values. A more provocative explanation for the differences
in sensitivity and specificity observed between study sites is
regional antigenic variability inH. pylori strains (16). If this
is the case, local validation of antibody test performance
characteristics may be necessary.
A limitation of our study protocol was the potential in-
clusion of patients tested forH. pylori .1 yr before upper
endoscopy. We have reviewed the records of the 131 pa-
tients enrolled in this study and no patients had been pre-
viously treated forH. pylori. Even if a small number of
previously treated patients had been enrolled, their effect on
the results would be minimal. In support of this statement,
we offer two arguments. First, studies have suggested that
between 35% and 94% of those successfully cured ofH.
pylori will experience seroconversion at 1 yr (17, 18). One
could argue that the percentage of patients expected to have
a negative whole blood antibody test 1 year afterH. pylori
eradication could be even higher as the published studies
have utilized very sensitive ELISAs. Consequently, only a
fraction of previously treated patients would be expected to
have a positive antibody test at the time of enrollment.
Perhaps more importantly, the inclusion of previously
treated patients would be expected to produce false positive
antibody test results and, in turn, adversely affect the spec-
ificity of these tests. In fact, the specificities of two of the
three whole blood antibody tests was.90%. We would
stress that the current data do not support the use of the
whole blood antibody tests as a method of establishingH.
pylori eradication.
We feel that the performance characteristics yielded by
the three whole blood antibody tests have important impli-
cations for the clinician. The ideal test for a “test and treat”
strategy would be both sensitive and specific forH. pylori
infection. However, faced with the choice of a more sensi-
tive or specific test, we would argue in favor of the more
sensitive test. AsH. pylori infection is clearly associated
with peptic ulcer disease (19, 20) and gastric malignancy
(20) and perhaps associated with nonulcer dyspepsia (21), it
is important to identify those individuals with infection.
Certainly for those dyspeptic patients with peptic ulcer
disease, the potential sequelae of undiagnosed infection,
both in terms of morbidity and of the health care resource
use associated with further evaluation and misguided ther-
apies, could be quite substantial. As such, clinicians using
whole blood antibody tests in the community should be
aware of their marginal sensitivities.
In conclusion, when histology was used as a gold stan-
dard, RUT proved superior to Flex Pak HP. There were no
statistically significant differences in the performance char-
acteristics of the three whole blood antibody tests evaluated.
The whole blood antibody tests yielded sensitivities of ques-
tionable acceptability. Clinicians should be aware of the
performance characteristics and limitations of these tests,
particularly when using them as a sole means of identifying
patients infected withH. pylori.
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